In this article, we will be taking a look at the 8 Best Small Cap Pharma Stocks to Buy Right Now.

Despite the concerns surrounding the Iran War, Haig Bathgate, CEO of Callanish Capital, stated on CNBC on May 7 that he was optimistic about global stocks. He said that while short-term market volatility and emotional responses are frequently caused by geopolitical crises, the long-term effects on stocks are minimal. Bathgate stressed the need for a historical perspective, pointing out that investors tend to overreact to crises while ignoring long-term structural factors. According to him, markets are influenced by global energy dynamics, capital expenditure cycles, and AI growth, even though the conflict may temporarily affect certain sectors. Additionally, he pointed out that fundamentals and long-term themes outweighed geopolitical noise, and U.S. markets had significant momentum toward the previous year’s close.

In addition, Citi’s Scott Chronert discussed whether investors should reenter the stock market in the face of uncertainty on CNBC’s “Closing Bell” on March 24. Two market narratives were described by him. Expectations for volatility and risk aversion increased as short-term positioning became defensive as the Iran situation worsened during the preceding three weeks. Recently, lessening tensions have supported a more optimistic market sentiment across stocks and riskier assets.

The intermediate prediction, on the other hand, is more complex and involves careful observation of interest rates, oil prices, currency fluctuations, and general liquidity circumstances. As the fiscal Q1 earnings season approaches, these factors will impact corporate fundamentals, which will impact investor attitude and advice. Long-term trends rely on profitability and macro confirmation, he continued, while short-term relief rallies are possible. He said that investors need to take into account structural growth factors, policy-driven market signals, and geopolitical shocks.

Together, these two analysts present a picture of a market that is impacted by the tension between short-term geopolitical shocks and also long term structural economic factors. Although geopolitical developments can dominate headlines and cause short-term volatility, both perspectives contend that investors are ultimately more concerned with earnings visibility, liquidity conditions, and long-term structural themes like innovation, productivity, and global energy transitions in the current context.

With that said, let’s take a look at the best pharmaceutical stocks.

Our Methodology

For our methodology, we screened for small-cap stocks with market capitalizations between $300 million and $2 billion. From this pool, we selected eight pharmaceutical stocks based on the latest news and developments, and then ranked them in ascending order by their total number of hedge fund holders as of Q4 2025, as tracked by the Insider Monkey database.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Here is a list of the 8 best small-cap pharma stocks to buy right now.

8. Organogenesis Holdings Inc. (NASDAQ:ORGO)

Number of Hedge Fund Holders: 16  

Market Capitalization: $310.0 million 

Organogenesis Holdings Inc. (NASDAQ:ORGO) is one of the best pharmaceutical stocks on our list.

TheFly reported on May 8 that BTIG downgraded ORGO to Neutral from Buy in a post–first-quarter update, with the price target withdrawn. The revised view reflects a slower-than-expected recovery in the Advanced Wound Care segment, with uncertainty around the timing of improvement. The report highlights that several market headwinds have weighed on the category, including reduced clarity in demand trends, lower utilization levels, and a shift among physicians toward simpler wound treatment options instead of more advanced dressings.

In a separate move, earlier on April 28, Organogenesis Holdings Inc. (NASDAQ:ORGO) completed the full rolling submission of its Biologics License Application to the U.S. FDA for ReNu, a cryopreserved amniotic suspension allograft intended for treating symptomatic knee osteoarthritis.

The filing process began in December 2025, when non-clinical sections were submitted first. With the latest step, the company has now delivered the remaining clinical data package along with chemistry, manufacturing, and controls documentation, finalizing the complete application package for regulatory review.

Organogenesis Holdings Inc. (NASDAQ:ORGO) is a regenerative medicine company that develops and commercializes tissue engineering and cell therapy products for advanced wound care and surgical applications, aiming to improve healing and patient outcomes.

7. Emergent BioSolutions Inc. (NYSE:EBS)

Number of Hedge Fund Holders: 20  

Market Capitalization: $429.80 million 

Emergent BioSolutions Inc. (NYSE:EBS) is one of the best pharmaceutical stocks to invest in.

TheFly reported on April 30 that EBS announced that Singapore’s Health Sciences Authority approved an expanded use of ACAM2000, allowing its use in preventing mpox in adults considered at elevated risk of infection. The decision broadens the vaccine’s application beyond its prior scope and supports its role in public health preparedness for emerging infectious threats. The company highlighted the approval as evidence of the strength and range of its medical countermeasure portfolio and emphasized continued engagement with global regulatory agencies to expand access to protective and life-saving medical solutions.

Separately, on April 29, Emergent BioSolutions Inc. (NYSE:EBS) announced a multi-year collaboration with SAB Biotherapeutics focused on development and manufacturing support for SAB-142, a clinical-stage candidate for autoimmune type 1 diabetes. The agreement is valued at roughly $50 million, with about $36 million tied to potential regulatory approval and future milestone achievements.

Under the partnership, EBS will provide full-scale development and manufacturing services aligned with current good manufacturing practices, including process optimization, scale-up activities, technology transfer, analytical method support, and clinical supply production. Commercial manufacturing support is also included, contingent on eventual regulatory clearance of the program.

Emergent BioSolutions Inc. (NYSE:EBS) is a global life sciences company that develops and manufactures vaccines, therapeutics, and other medical countermeasures for public health threats like infectious diseases, chemical/biological agents, and opioid overdoses.